Robert E. Walker Form 3 Filing and Power of Attorney for Novavax, Inc.

This SEC Form 3 filing reports the initial beneficial ownership of securities by Robert E. Walker, Executive Vice President of R&D at Novavax, Inc. The filing discloses Walker's holdings as of April 14, 2026, including 34,386 shares of common stock and multiple equity awards. The filing includes six derivative holdings: three stock option grants with exercise prices ranging from $6.97 to $10.11 and three restricted stock unit grants, all with various vesting schedules through March 2026. The options have expiration dates extending to 2036. The filing also contains a Power of Attorney document where Walker authorizes three company executives (John C. Jacobs, James P. Kelly, and Mark J. Casey) to file Forms 3, 4, and 5 on his behalf for Section 16 compliance. This is a standard initial ownership filing for a corporate officer.